Vectoring In On Verastem [Seeking Alpha]
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Seeking Alpha
AF co-pack's addressable U.S. market is ~$2.6B in prevalence, with peak sales opportunity estimated at $750M for the current indication. RAMP 301 trial's expansion to 299 patients may improve odds for key endpoints; pivotal readout is expected mid-2027, with EU/Japan filings contingent on results. An analysis around Verastem follows in the paragraphs below. Looking for a helping hand in the market? Members of The Busted IPO Forum get exclusive ideas and guidance to navigate any climate. Learn More » Lars Neumann/iStock via Getty Images Shares of oncology concern Verastem, Inc. ( VSTM are down by roughly 40% since putting in a (then) 16-month high in September 2025 as three events surrounding its recently approved therapy weigh. Sold as Avmapki Fakzynja (AF) co-pack, its label expansion opportunities More on my IG service Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum . Tr
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem (VSTM) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VSTM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "selMarketBeat
- Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.MarketBeat
- Verastem (VSTM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s CancersBusiness Wire
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
VSTM
Earnings
- 3/4/26 - Beat
VSTM
Sec Filings
- 4/9/26 - Form DEF
- 3/27/26 - Form SCHEDULE
- 3/23/26 - Form 4
- VSTM's page on the SEC website